Mundo: Marketing Authorisation Application for lecanemab submitted in Great Britain: BioArctic (2)

(Información remitida por la empresa firmante)

[1] Protofibrils are large Aß aggregated soluble species of 75-5000 Kd[2] Mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/marketing-authorisation-application-for-lecanemab-submitted-in-great-britain-bioarctic-301830416.html